Literature DB >> 11942498

Proton MR spectroscopic imaging in multiple sclerosis.

G Tedeschi1, S Bonavita, H F McFarland, N Richert, J H Duyn, J A Frank.   

Abstract

We studied 24 patients with multiple sclerosis (MS) by proton magnetic resonance spectroscopic imaging (1H-MRSI) to assess the neurochemical pathology of the white-matter lesions (WML) and normal-appearing white matter (NAWM). Our 1H-MRSI technique allowed simultaneous measurement of N-acetylaspartate (NAA), choline-containing compounds (Cho), and creatine plus phosphocreatine (Cr) signal intensities from four 15-mm slices divided into 0.84 ml single-volume elements. In WML we found significantly lower NAA/Cr and NAA/Cho ratios and a significantly higher Cho/Cr ratio than in NAWM or control white matter. In NAWM, NAA/Cr and Cho/Cr were significantly lower than in control white matter. 1H-MRSI was compatible with damage to myelin in WML, and with axonal damage and/or dysfunction in WML and NAWM. These findings extend data on involvement of NAWM in MS beyond the abnormalities visible on MRI.

Entities:  

Mesh:

Year:  2002        PMID: 11942498     DOI: 10.1007/s002340100584

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  9 in total

Review 1.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

2.  Hippocampal extracellular GABA correlates with metabolism in human epilepsy.

Authors:  J W Pan; I Cavus; J Kim; H P Hetherington; D D Spencer
Journal:  Metab Brain Dis       Date:  2008-09-18       Impact factor: 3.584

3.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

4.  The basal ganglia: a substrate for fatigue in multiple sclerosis.

Authors:  N Téllez; J Alonso; J Río; M Tintoré; C Nos; X Montalban; A Rovira
Journal:  Neuroradiology       Date:  2007-10-23       Impact factor: 2.804

Review 5.  High field MRI in the diagnosis of multiple sclerosis: high field-high yield?

Authors:  Mike P Wattjes; Frederik Barkhof
Journal:  Neuroradiology       Date:  2009-03-11       Impact factor: 2.804

6.  MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study.

Authors:  J Bellmann-Strobl; H Stiepani; J Wuerfel; G Bohner; F Paul; C Warmuth; O Aktas; K P Wandinger; F Zipp; R Klingebiel
Journal:  Eur Radiol       Date:  2009-03-24       Impact factor: 5.315

Review 7.  Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis.

Authors:  Oun Al-Iedani; Jeannette Lechner-Scott; Karen Ribbons; Saadallah Ramadan
Journal:  J Biomed Sci       Date:  2017-02-28       Impact factor: 8.410

8.  Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Authors:  Ian Marshall; Michael J Thrippleton; Mark E Bastin; Daisy Mollison; David A Dickie; Francesca M Chappell; Scott I K Semple; Annette Cooper; Sue Pavitt; Gavin Giovannoni; Claudia A M Gandini Wheeler-Kingshott; Bhavana S Solanky; Christopher J Weir; Nigel Stallard; Clive Hawkins; Basil Sharrack; Jeremy Chataway; Peter Connick; Siddharthan Chandran
Journal:  J Neurol       Date:  2018-05-30       Impact factor: 4.849

Review 9.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.